Clinical trials: DENGUE
Dengue Fever
A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT06579755
- Testing
- TDV
- Where
- 7 sites in Argentina, Brazil and 2 more
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Takeda
Randomised Clinical Trial, Double Blind
Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults
This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study. Forty-two flavivirus-naïve adults will be enrolled and will receive 3 administrations of VLPDEN-02 or control at days 0, 28, and 56.
- Conditions
- Randomised Clinical Trial, Double Blind, Dengue, Challenge Test
- Trial name
- NCT07831473
- Testing
- VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- VLP Therapeutics
Dengue
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
- Trial name
- NCT06006559
- Testing
- EYU688
- Where
- 27 sites in Brazil, Colombia and 5 more
- Volunteers
- 108 people
- Sponsor
- Novartis Pharmaceuticals
Dengue Fever
Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose
The purpose of this study is to describe antibody persistence for each of the 4 dengue serotypes for up to 63 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-315…
- Trial name
- NCT03999996
- Testing
- Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
- Where
- 10 sites in United States, Mexico
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT07047521
- Testing
- Tetravalent Dengue Vaccine (TDV)
- Where
- 5 sites in Australia
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue
A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)
This is a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.
- Trial name
- NCT07576868
- Testing
- CP-COV03
- Where
- 2 sites in Vietnam
- Volunteers
- 210 people
- Sponsor
- Hyundai Bioscience Co., Ltd.
Dengue Fever
A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT06665035
- Testing
- TDV
- Where
- 4 sites in Colombia, Thailand
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia
The main aim of this study is to collect the number and type of medical problems (adverse events) after vaccination with QDENGA in Malaysia and to learn more about such medical problems after vaccination.
- Trial name
- PRIME-Q (NCT06388785)
- Testing
- No Intervention
- Where
- 2 sites in Malaysia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
IC14 in Adult Patients With Dengue Fever
Randomized, double-blind, placebo-controlled, safety, PK/PD and preliminary efficacy study of intravenous IC14 in adult patients in a dengue-endemic region presenting with fever > 38°C for < 48 hours with a positive NS1 strip…
- Trial name
- NCT03875560
- Testing
- IC14
- Sponsor
- Implicit Bioscience
Dengue Fever
A Study in Children and Teenagers to Learn if a TDV Dengue Vaccination Lowers the Chance of Hospital Stays for Dengue
The main aim of this study is to collect more information on the effectiveness of TDV when used in a pilot public vaccination program for children and adolescents participating in a community-based cohort in Southeast Asian…
- Trial name
- NCT06843226
- Testing
- No Intervention
- Where
- 7 sites in Indonesia, Malaysia and 1 more
- Volunteers
- 70,000 people, healthy volunteers welcome
- Sponsor
- Takeda
Malaria Fever, Zika
Xpert® Tropical Fever Test on GeneXpert® Edge X System
This is a multi-site, observational, cross-sectional clinical study that includes geographically diverse sites within and outside the United States.
- Conditions
- Malaria Fever, Zika, Dengue Fever, Leptospirosis
- Trial name
- NCT07520279
- Testing
- Xpert Tropical Fever test
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Cepheid
DENV-3 Controlled Human Infection Model
A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
The goal of this clinical trial is to determine the prophylactic and therapeutic effect of AV-1 in healthy adults using a DENV-3 controlled human infection model (CHIM)
- Trial name
- NCT06799741
- Testing
- AV-1 100 mg, AV-1 300 mg, AV-1 900 mg
- Where
- 3 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- AbViro LLC
Dengue Virus Infection
Dengvaxia US Pregnancy Registry
The primary objective of this study is to assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women and their offspring(s) vaccinated with Dengvaxia during their pregnancy
- Trial name
- DNG00044 (NCT04486638)
- Testing
- Dengue Tetravalent Vaccine, Live
- Where
- Puerto Rico
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan
Dengue fever is caused by an infection with the dengue virus. Vaccination with TDV can help prevent dengue fever. The main purpose of this study is to learn about TDV's ability to create an immune response in adults, adolescents…
- Trial name
- NCT06741683
- Testing
- TDV
- Where
- 5 sites in Japan
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue
Study to Examine the Effects of Oral Fenretinide
This randomized, placebo controlled single center study examines the extent to which 600 mg/m2/day of orally administered ISLA101 (fenretinide), given prophylactically or therapeutically, may reduce or eliminate signs and…
- Trial name
- PROTECT (NCT06528457)
- Testing
- ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Island Pharmaceuticals
Dengue
Dengue - Sample Collection Study Pakistan
The objective of this study is to collect well-characterized serum and plasma specimens from confirmed dengue positive and dengue negative subjects to support dengue diagnostic products development.
- Trial name
- NCT07203183
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Abbott Rapid Dx
Dengue Fever
Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults
The purpose of this study is to assess the neutralizing antibody response against each dengue serotype post-vaccination.
- Trial name
- NCT03746015
- Testing
- TDV
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia
The primary objective of the study is to identify any suspected dengue case in subjects that received at least one dose of the CYD dengue vaccine who were classified as seronegative or undetermined at baseline (according to…
- Trial name
- CYD00082 (NCT04113330)
- Where
- Colombia
- Volunteers
- 918 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue
A Study of JNJ-64281802 for the Prevention of Dengue Infection
The purpose of this study is to evaluate the prophylactic effect of JNJ-64281802 with respect to the prevention of laboratory-confirmed dengue virus (DENV) infection up to the last day of dosing among participants who have no…
- Trial name
- NCT05201794
- Testing
- JNJ-64281802
- Where
- 38 sites in Brazil, Colombia and 7 more
- Volunteers
- 1,595 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Dengue Disease, Dengue Virus
Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)
The primary objective of this study is to compare the dengue virus-neutralizing antibody geometric mean titers (GMTs) for each of the 4 dengue serotypes (DENV1, DENV2, DENV3, and DENV4) at Day 28 post-vaccination for participants…
- Trial name
- NCT05507450
- Testing
- V181 High-Potency Level, V181 Mid-Potency Level, V181 Low-Potency Level
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 1,271 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC